China Sets Aside RMB 2.7 Billion To Advance Biopharma Tech
This article was originally published in PharmAsia News
Executive Summary
This year, China’s National Development Reform Commission has earmarked RMB 1.2 billion in funding for projects relating to development of generics and protein biopharma and vaccines.